Eculizumab is FDA approved specialized drug that is used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS). It is indicated in both adult and paediatric patients. Soliris is the brand name used for commercial purposes and this drug is promoted by Alexion. This is the same company credited for the discovery and research development of Eculizumab. The role of Soliris as a choice of therapy has expanded to other indications that include an Orphan indication like Idiopathic membranous glomerular nephropathy. This drug is also used in the renal transplantation for the prevention of delayed graft function. Eculizumab in India is often imported on emergency basis.

The role of Soliris in India is often perceived in critical care settings. However, the scope of recommending this drug by the Haematologists & Transplant Experts is more. The access of this drug is also understood to be a concern. But, there are always ways and means to legally source it through effective channels. This medication is administered through IV infusion and is known for its mechanism that reduces the destruction of RBCs. This would significantly reduce the need for blood transfusion.

The ongoing research and the data emerging from clinical trials would point towards positive outcomes in new therapeutic possibilities. Soliris is available as 300mg vails. It is also explored for the treatment possibility of CHAPLE syndrome. There are several genetic disorders that are rare in incidence that can be treated by new and advanced medications.